Physician profile
Eric Wilkinson
NPI 1396442232
$6,284.26
in general payments reported to CMS, 2019-2025
20 companies · $3,333 in 2025
The $3,333 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,275 · 2024: $1,677 · 2025: $3,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,284.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $909.02 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $695.83 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $683.12 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $650.24 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $640.92 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $541.94 | 2023-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $454.81 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $453.08 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $295.92 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $194.06 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $189.27 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $185.84 | 2023-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $120.42 | 2024 | Qelbree |
| Corium, LLC | $83.04 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $64.71 | 2024 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $46.49 | 2023-2024 | Perseris, Sublocade |
| Acadia Pharmaceuticals INC | $25.50 | 2025 | Daybue |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.73 | 2024 | Abilify Maintena |
| Almatica Pharma LLC | $16.44 | 2023 | Loreev Xr |
| Tris Pharma INC | $14.88 | 2023 | Quillivant, Dyanavel Xr, Quillichew Er |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.